These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25333374)

  • 21. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
    Almalla M; Pross V; Marx N; Hoffmann R
    Coron Artery Dis; 2012 Nov; 23(7):492-6. PubMed ID: 22990414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Approach to coronary bifurcation lesions using the everolimus-eluting stent: comparison between a simple strategy and a complex strategy with T-stenting.
    Ruiz-Salmerón RJ; Valenzuela LF; Pérez I; Fuentes M; Rodríguez-Leiras S; Vizcaíno M; Carrascosa C; Marcos F
    Rev Esp Cardiol (Engl Ed); 2013 Aug; 66(8):636-43. PubMed ID: 24776332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repeat drug-eluting stent implantation for in-stent restenosis: first- or second-generation stent.
    Yamashita K; Ochiai M; Yakushiji T; Ebara S; Okabe T; Yamamoto MH; Saito S; Hoshimoto K; Isomura N; Araki H; Obara C
    J Invasive Cardiol; 2012 Nov; 24(11):574-8. PubMed ID: 23117311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention).
    Taniwaki M; Stefanini GG; Silber S; Richardt G; Vranckx P; Serruys PW; Buszman PE; Kelbaek H; Windecker S;
    J Am Coll Cardiol; 2014 Apr; 63(16):1617-25. PubMed ID: 24530680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients.
    Dibra A; Kastrati A; Mehilli J; Pache J; Schühlen H; von Beckerath N; Ulm K; Wessely R; Dirschinger J; Schömig A;
    N Engl J Med; 2005 Aug; 353(7):663-70. PubMed ID: 16105990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods.
    Serruys PW; Ormiston JA; Onuma Y; Regar E; Gonzalo N; Garcia-Garcia HM; Nieman K; Bruining N; Dorange C; Miquel-Hébert K; Veldhof S; Webster M; Thuesen L; Dudek D
    Lancet; 2009 Mar; 373(9667):897-910. PubMed ID: 19286089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiographic outcomes with biodegradable polymer and permanent polymer drug-eluting stents.
    Kufner S; Massberg S; Dommasch M; Byrne RA; Tiroch K; Ranftl S; Fusaro M; Schömig A; Kastrati A; Mehilli J;
    Catheter Cardiovasc Interv; 2011 Aug; 78(2):161-6. PubMed ID: 21400652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Everolimus-eluting stent for the treatment of bare metal in-stent restenosis: clinical and angiographic outcomes at nine-month follow-up of XERES (Xience Evaluation in bare metal stent REStenosis) trial.
    Carrié D; Delarche N; Piot C; Berland J; Menneveau N; Bonello L; Py A; Teiger E; Leborgne L; Bayet G; Wittenberg O; Schiele F
    EuroIntervention; 2014 Oct; 10(6):700-8. PubMed ID: 24334825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical outcomes in the percutaneous coronary intervention of in-stent restenosis with everolimus-eluting stents.
    Lee MS; Yang T; Mahmud E; Park KW; Kim HS; Kim MH; Dangas G; Hermiller J; Krucoff M; Rutledge D
    J Invasive Cardiol; 2014 Sep; 26(9):420-6. PubMed ID: 25198484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial.
    Kim WJ; Lee SW; Park SW; Kim YH; Yun SC; Lee JY; Park DW; Kang SJ; Lee CW; Lee JH; Choi SW; Seong IW; Lee BK; Lee NH; Cho YH; Shin WY; Lee SJ; Lee SW; Hyon MS; Bang DW; Park WJ; Kim HS; Chae JK; Lee K; Park HK; Park CB; Lee SG; Kim MK; Park KH; Choi YJ; Cheong SS; Yang TH; Jang JS; Her SH; Park SJ;
    Circulation; 2011 Aug; 124(8):886-92. PubMed ID: 21810659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial.
    Hofma SH; Brouwer J; Velders MA; van't Hof AW; Smits PC; Queré M; de Vries CJ; van Boven AJ
    J Am Coll Cardiol; 2012 Jul; 60(5):381-7. PubMed ID: 22835668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of limus-eluting stents and balloon angioplasty for sirolimus-eluting in-stent restenosis.
    Ota H; Mahmoudi M; Kitabata H; Torguson R; Chen F; Satler LF; Suddath WO; Pichard AD; Waksman R
    Cardiovasc Revasc Med; 2015 Mar; 16(2):84-9. PubMed ID: 25870152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of diabetes on the benefits from everolimus-eluting stent as compared to first-generation drug-eluting stent in patients with ST elevation myocardial infarction.
    De Luca G; Sauro R; Capasso M; Lanzillo T; Manganelli F; Carbone G; Lanni F; Pagliuca MR; Palmieri V; Serino V; Rosato G; Suryapranata H; Di Lorenzo E
    Diab Vasc Dis Res; 2015 Sep; 12(5):306-14. PubMed ID: 26150193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three-year follow-up after treatment of bare-metal stent restenosis with first-generation or second-generation drug-eluting stents.
    Almalla M; Schröder JW; Pross V; Marx N; Hoffmann R
    Coron Artery Dis; 2013 Mar; 24(2):165-70. PubMed ID: 23242011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial.
    von Birgelen C; Sen H; Lam MK; Danse PW; Jessurun GA; Hautvast RW; van Houwelingen GK; Schramm AR; Gin RM; Louwerenburg JW; de Man FH; Stoel MG; Löwik MM; Linssen GC; Saïd SA; Nienhuis MB; Verhorst PM; Basalus MW; Doggen CJ; Tandjung K
    Lancet; 2014 Feb; 383(9915):413-23. PubMed ID: 24183564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial.
    Wiemer M; Serruys PW; Miquel-Hebert K; Neumann FJ; Piek JJ; Grube E; Haase J; Thuesen L; Hamm C
    Catheter Cardiovasc Interv; 2010 Jun; 75(7):997-1003. PubMed ID: 20517959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized trial of optimal treatment strategies for in-stent restenosis after drug-eluting stent implantation.
    Song HG; Park DW; Kim YH; Ahn JM; Kim WJ; Lee JY; Kang SJ; Lee SW; Lee CW; Park SW; Han S; Seong IW; Lee NH; Lee BK; Lee K; Lee SW; Nah DY; Park SJ
    J Am Coll Cardiol; 2012 Mar; 59(12):1093-100. PubMed ID: 22421303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.